Article and Video CATEGORIES

Cancer Journey

Search By

Cesar A. De Las Casas, MD, MPH, board-certified hematologist and oncologist. He earned his medical degree from the Universidad Peruana Cayetano Heredia in Lima in 1994. He completed his internship in internal medicine at the Baylor College of Medicine in 1999, serving as Chief Medical Resident at St. Luke’s Episcopal Hospital in Houston and at Ben Taub Hospital in 1999 and 2000.

Spanish Blood Cancer Library - Is there a preferred induction therapy?
Fri, 11/17/2017 - 18:09
¿Hay alguna terapia de inducción preferida?
Author
Cesar A. De Las Casas, MD, MPH, GRACE Faculty

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there a preferred induction therapy (¿¿Hay alguna terapia de inducción preferida?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Multiple Myeloma, (Mieloma Múltiple).


Transcription:

¿Hay alguna terapia de inducción preferida?

El tratamiento del mieloma múltiple debe de ser individualizado y centrado en las características del paciente, en la presencia o no de otras enfermedades, comorbilidades, las características citogenéticas y moleculares. Todas estas características van a ser importantes para diseñar el tratamiento inicial o de inducción para estos pacientes.

Existen distintos esquemas de categorización o de riesgo bajo, intermedio o alto que permiten al clínico presentar al paciente distintas opciones. El caso más usado en Norte América es la combinación de bortezomib que es un inhibidor de proteosoma con ciclofosfamida y dexametasona. También se usa la combinación de bortezomib con lenalidomida y dexametasona.

Estos esquemas son comparables y van a ser las combinaciones más frecuentemente usadas, no siendo las únicas. Hay otras combinaciones de 2 fármacos como bortezomib y dexametasona, o lenalidomida y dexametasona, pero estos van a depender de las características particulares de cada paciente y la firma molecular y a nivel citogenético.

Mieloma múltiple cada vez se considera más como un grupo de enfermedades que una sola enfermedad que se puede encasillar en un solo tratamiento.

 

­­­­­­­­­­­­

Is there a preferred induction therapy?

The treatment for multiple myeloma needs to be personalized and patient-centered, it has to be based on the presence or absence of diseases, comorbidities, cytogenetics and molecular characteristics. All these characteristics will be important to design the initial or induction treatment in these patients.

There are several schemes that categorize based on the low, intermediate or high risk, that allow us to be ready with many options for the patient. The most used case in North America is the combination of bortezomib, a proteasome inhibitor, with cyclophosphamide and dexamethasone. We also use the combination of bortezomib with lenalidomide and dexamethasone.

These treatments will be the most used, but they are not the only options. There are other combinations of 2 drugs like bortezomib with dexamethasone or lenalidomide and dexamethasone, but these combinations depend on the particular characteristics of the patient, and their molecular and cytogenetic characteristics.

Multiple myeloma is now considered as a group of diseases, and not as a single disease that can only use one treatment.


 

We would like to thank the following company for their support of this program:

 


 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Spanish Targeted Therapy Lung Cancer Patient Forum 2023
Video
2023 Terapias Dirigidas en el Foro de Pacientes con Cáncer de Pulmón El vídeo completo sin editar está disponible On Demand   View HERE  
Image
Spanish TTF 2023
Article
Únete a nosotros, sábado 12 de agosto a las 9:00 a.m.  En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras.  
Image
Targeted Therapies in Lung Cancer Patient Forum 2023
Article
Thank you for joining us on Saturday for the 2023 Targeted Therapies in Lung Cancer Patient Forum! The full unedited versions of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage and Second Stage, are now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks.  

Forum Discussions

Hi, I'm sorry you're having these issues.  The type of shoulder pain that feels like nerve pain is most likely nerve pain.  The type of tumor that causes similar shoulder pain...

Thank you so much for the response! I have seen a lot of your post on here and it's really awesome of you to take the time to reply to all...

ONKTALK is tomorrow. 

I hope to see you there.

The forum is now available on demand here.  Don't hesitate to ask questions as they come up. 

Take care,

Janine

Hi happybluesun,  Welcome to Grace.   I'm sorry your mom is going through this. 

 

Driver mutations are mutations that drive (or cause) the cancer.  Having more than one driver mutation is...

Hi Janine, thank you very much for your reply. As of June 2023, my mom has been prescribed Almonertibi Mesilate Tablet, a targeted therapy medicine made by the Chinese company Haosen...

Recent Comments

JOIN THE CONVERSATION
Thank you so much for the…
By Worried472 on Tue, 09/26/2023 - 12:44
Hi, I'm sorry you're having…
By JanineT GRACE … on Tue, 09/26/2023 - 11:24
The forum is now available…
By JanineT GRACE … on Mon, 09/25/2023 - 14:10
Reminder
By JanineT GRACE … on Fri, 09/22/2023 - 15:50